AHAP (PT Asuransi Harta Aman Pratama Tbk.) is gearing up for a significant rights issue, a strategic move designed to inject crucial capital for working operations and, critically, to meet stringent regulatory requirements from the Financial Services Authority (OJK). This corporate action, involving the issuance of up to 3.5 billion new shares, presents both opportunities and challenges for existing and prospective shareholders, reshaping the insurer’s financial landscape.

Key Details of AHAP’s Rights Issue: Dates and Dilution

The insurer has finalized its updated rights issue schedule, providing clarity for investors. The cum rights date for both the regular and negotiation markets is now set for October 6, 2026. Following this, the trading and exercise period for these rights will run from October 12 to October 16, 2026.

Under this scheme, AHAP plans to issue a substantial number of new shares, totaling up to 3.5 billion, at an exercise price of Rp50 per share. The ratio for this offering is seven existing shares for every five rights, which could lead to a significant dilution effect of up to 41.67% for shareholders who do not exercise their rights. This potential dilution underscores the importance for investors to actively consider their participation.

Strategic Capital Infusion: Meeting OJK Mandates and Fueling Operations

The capital raised from this rights issue is earmarked for two primary objectives. Firstly, it will bolster AHAP’s working capital, providing the operational liquidity necessary for sustained business growth. Secondly, and perhaps more critically, the funds are aimed at fulfilling the OJK’s mandate for a minimum insurance company equity of Rp250 billion by December 31, 2026. This regulatory compliance is a non-negotiable cornerstone for AHAP’s continued operation and stability in the Indonesian insurance sector.

A strong vote of confidence comes from AHAP’s controlling shareholder, PT Asuransi Central Asia (ACA). ACA has publicly committed to exercising its full rights entitlement, demonstrating unwavering support for the company’s financial strengthening. This commitment will be realized through a combination of a cash payment totaling approximately Rp79.5 billion and the conversion of a subordinated loan worth Rp30 billion. This dual approach not only injects cash but also streamlines AHAP’s balance sheet by reducing debt.

Implications for AHAP Investors: Navigating the Path Ahead

For current AHAP shareholders, the rights issue presents a critical decision point. While the potential dilution of 41.67% is substantial, exercising the rights allows investors to maintain their proportional ownership and participate in the company’s future growth. The infusion of capital, especially for OJK compliance, acts as a stabilizing force, fortifying AHAP’s regulatory standing and operational foundation.

This capital raise is more than just a financial transaction; it’s a strategic pivot. By securing the required equity, AHAP aims to remove a significant regulatory overhang, allowing management to focus squarely on enhancing its core insurance business and expanding market reach. Investors should view this as a necessary step towards building a more resilient and compliant insurer.

What Should AHAP Shareholders Do?

• Evaluate Dilution: Understand the impact if you do not participate. Your percentage ownership will decrease significantly.
• Assess Future Prospects: Consider AHAP’s long-term business strategy and the positive implications of meeting OJK’s equity requirements.
• Act on Dates: Mark October 6, 2026 (cum rights) and October 12-16, 2026 (trading/exercise) on your calendar to ensure timely action if you choose to participate.

The upcoming AHAP rights issue is a defining moment, addressing both immediate capital needs and long-term regulatory compliance. With the backing of its major shareholder, this corporate action positions AHAP to meet its regulatory obligations and, in turn, potentially unlock new avenues for sustainable growth in Indonesia’s dynamic insurance landscape.